ValueTheMarkets Logo
Stock Market Review for the Retail Investor
Market Flashes

Creso’s wholly owned Canadian subsidiary Mernova Medicinal Inc. secures four new purchase orders (POs) totalling C$494,131 (A$502,1991)

17 Feb 2021 | by: ValueTheMarkets

Highlights

  • Purchase orders (POs) received for Ritual Green products highlight significant demand
  • $343,331 ($348,7261) in POs from the Ontario Cannabis Store mark Mernova’s entry into Canada’s largest recreational cannabis market
  • Additional POs from Cannabis NB in New Brunswick and Nova Scotia Liquor Corporation highlight a shift towards recurring revenue model
  • Launch of new Black Mamba strain and pre-roll joint range expected to grow revenues
  • Additional POs for Ritual Green products to materialise in the coming months
  • Mernova is on track to deliver a record quarter of POs
  • Continued repeat orders and customer uptake is highlighting Mernova to be a strong revenue generator
  • The shortened interval between receiving new POs and the growing value of each PO is extremely encouraging – outlook for remainder for financial year is extremely positive.

Creso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to advise that it’s wholly-owned Canadian subsidiary Mernova Medicinal Inc. (“Mernova”), has secured four purchase orders (“PO”) for its leading Ritual Green product range, with a total value of C$494,131 (A$502,1991).

Mernova has received two separate purchase orders from the Ontario Cannabis Retail Corporation (“OCRC”), which operates as the Ontario Cannabis Store (“OCS”), valued at C$228,323 ($A231,9111) and C$115,008 (A$116,8151), for a total value of C$343,331 (A$348,7261).

The OCS is a crown agency solely owned by the Province of Ontario. It reports directly to the Ministry of Finance and is Ontario’s only retailer and wholesaler of legal recreational cannabis. The group provides legal cannabis to a large customer base through Health Canada approved suppliers. Ontario is currently Canada’s largest recreational cannabis market and represents a major opportunity for the Company.

Mernova was formally recognised as a supplier to the OCS during December 2020 (refer ASX announcement: 16 December 2020). The initial POs are for the Company’s Ritual Green products, which will be sold through established stores and the OCS online sales platform.

The Company expects to deliver the first purchase order in the coming weeks, with the second PO to be completed shortly thereafter. Creso anticipates ongoing orders from the OCS over the coming months, and expects them to increase in size and volume as Ritual Green’s market share continues to grow across Ontario.

Mernova has also secured a repeat purchase order from Cannabis NB, New Brunswick’s only legal cannabis retailer, valued at C$81,800 (A$83,4021) for an assortment of its Ritual Green cannabis strains. Cannabis NB is the government-owned retail cannabis monopoly in the Province of New
Brunswick. The group has an established footprint, boasting 20 retail outlets across the province, as well as an online sales platform.

This is the second PO the Company has received from Cannabis NB (refer ASX announcement: 3 February 2021), highlighting the considerable demand Mernova is witnessing for its products. The Company has also secured a C$69,000 (A$70,3521) order from the Nova Scotia Liquor Corporation (“NSLC”) for its Lemon Haze strain, which will be delivered by the end of the month. This marks the ninth PO for Mernova’s products in Nova Scotia, highlighting the Company’s recurring revenue model.

Mernova expects additional purchase orders across all provinces to continue to materialise in the near term, adding to its growing revenue profile. The Company expects additional POs to include its recently launched Black Mamba strain. Black Mamba is an Indica dominant strain, testing at over
20%+ THC content. It has been developed from the well known and sought after cannabis stains Grand Daddy Purple and Black Domina.

The Company also has a number of growth initiatives pending, including the launch of its pre-roll joint range, and entry into the emerging hash market. Mernova is also exploring a number of potential licencing agreements that may significantly scale up operations.


1 Based on the CADAUD exchange rate of ~$1.02.


Management Commentary

Mernova Managing Director, Jack Yu said:

“We are very pleased with the strong demand that we are witnessing for our Ritual Green Brand across Canada and the opportunities that are beginning to materialise. Importantly, these purchase orders mark the Company’s entry into Ontario, which is Canada’s largest recreational cannabis market.”

“We anticipate that purchase orders will continue to grow in frequency, size and volume, especially with the launch of our latest premium, artisanal, craft strain, Black Mamba. To support the launch and increase brand awareness, Mernova has initiated a number of branding and sales campaigns, including on social media, in coordination with high profile Canadian influencers.”

“We will utilise these marketing tools to promote the launch of other products in the pipeline, including our pre-roll joint range, which will significantly increase the number of options available in our product line, and grow our customer base and market share. Mernova has a number of growth initiatives planned in the coming months, and we look forward to providing regular updates to shareholders.”

Authority and Contact Details

This announcement has been authorised for release by the Board of Creso Pharma Limited.

Released through:
Ben Jarvis
Six Degrees Investor Relations
Ph: +61 (0) 413 150 448

For further information, please contact:
Investor Enquiries
EverBlu Capital
E: [email protected]
P: +61 2 8249 0000

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations.

The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.


IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by CRESO PHARMA LTD. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of five hundred thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

CHANGES IN SHARE TRADING AND PRICE

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

NO OFFER TO SELL OR BUY SECURITIES

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.

INFORMATION

Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.

NO FINANCIAL ADVICE

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

FORWARD LOOKING STATEMENTS

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

TERMS OF USE AND DISCLAIMER

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.

INTELLECTUAL PROPERTY

All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.

AUTHORS: VALUETHEMARKETS

valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.

Valuethemarkets.com, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

    RNS Responses